Washington University >> School of Medicine >>
  
Left Header Image Right Header Image Right Header Image Right Header Image
Skip Navigation Links
News
Faculty
Specialties
Research
Clinical Studies
 in 
babyfoot PEDS Home
Medschool Home
Skip Navigation Links
Home
Clinical Services
Programs
Research
Fellowship
Faculty
Contact Us
 
Hematology and Oncology | Fellowships


 

 


 

 

Introduction

The division has a nationally recognized fellowship program designed to train specialist pediatricians seeking a career in academic pediatric hematology/oncology.  Since our faculty has considerable strength in clinical and basic investigation, the program is well suited to candidates interested in both tracks.  The program strives to not only make the trainee highly skilled in clinical care, but also capable of designing and performing sophisticated biomedical investigation that focuses on understanding and treating the childhood diseases as broadly defined by our specialty.
 
In order to train physicians appropriately for careers in this field, the fellowship lasts "three-plus" years.  The first-year fellow has strictly clinical responsibilities with every third week on call from home.  In addition to six months as supervisor of the in-house clinical service, the fellow rotates on electives in laboratories such as coagulation/blood bank, HLA lab, cyogenetics, molecular diagnostics and clinical services including radiation therapy, pathology, pheresis, adult hematology and bone marrow transplant.  This broad curriculum provides a strong foundation for the fellow ensuring that he or she is well equipped with an extensive and sophisticated fund of knowledge.
 
After the first year, the fellow begins an individualized program of clinical or basic science investigation mentored by a faculty investigator at the School of Medicine.  During this period, the trainee is expected to develop the knowledge, thought processes and laboratory skills necessary to develop into an independent, competitive investigator in today's scientific community.  In order to focus on his or her investigation, the fellow's clinical responsibilities are limited to attending one clinic day each week and two clinical conferences.
The program has a long history of developing successful physician investigators.  Our fellows have published numerous articles in highly competitive areas of biomedical research, and they continue to maintain a history of success in acquiring extramural funding support.  Thus, fellows who graduate from our program can be confident that they will meet the challenges they will face as they advance through their academic careers.

 

Current Fellows

Samuel Anim, M.D. 

  • M.D. – University of Science and Technology Medical School, Ghana, 2001
  • Residency – Michigan State University/The Children's Hospotal at Bronson, Kalamazoo, MI, 2006-2009
  • Currently proceeding through the clinical first year rotations
Sharon McDonald, M.D. 
  • M.D. – University of Mississippi, 2004
  • Residency – University of Arkansas/Little Rock Children's Hospital, 2004-2007
  • Research: Characterization of the role of dyskerin, the known defective protein in dyskeratosis congenita, in the repair of damaged DNA
Laura Schuettpelz, M.D., Ph.D.
  • M.D. – Northwestern University School of Medicine, 2005
  • Residency – Washington University School of Medicine, 2005-2008
  • Research: Elucidating the role of G-CSF on hematopoietic stem cells
Edward Ziga, M.D.
  • M.D. – University of Science and Technology Medical School, Ghana, 1990
  • Residency – St. Joseph's Children's Hospital, New Jersey, 2004 - 2007
  • Currently proceeding through the clinical first year rotations

 

Awards and Grants Received by Current and Past Fellows

  1. National Research Service Award, NCI, 1991
  2. Functional Domains of NGF-IA, National Research Service Award, NIH, 1991
  3. Regulation of Lens Gap Junctions, National Research Service Award, NIH, 1991
  4. National Research Service Award, NIH, 1992
  5. Howard Hughes Medical Institute, Postdoctoral Fellowship, 1993
  6. American Cancer Society Post Doctoral Fellowship, 1993
  7. Pfizer Inc. Postdoctoral Fellowship, 1993
  8. American Association for Cancer Research, 1992
  9. American Heart Association Missouri Affiliate Fellowship, 1994
  10. Pediatric Medical Oncology Physician Scientist Award NIH, 1992
  11. Leukemia Society Fellowship Award, 1993
  12. Clinical Investigator Development Award NIH, 1994
  13. American Cancer Society Clinical Oncology Fellowship, 1994
  14. Pediatric Oncology Physician Scientist Award, 1994
  15. Robert Steel Foundation Research Fellowship, 1994
  16. Howard Hughes Medical Institute, Postdoctoral Research Fellowship for Physicians, 1995
  17. Clinical Investigator Development Award NIH, 1995
  18. Pediatric Medical Oncology Physician scientist Award, NIH, 1995
  19. American Cancer Society Clinical Oncology Fellowship, 1995
  20. Children's Brittle Bone foundation Fellowship, 1996
  21. American Heart Association Missouri Affiliate Fellowship, 1996
  22. Cure Foundation Fellowship, 1996
  23. American Society for Hematology, Fellow Award, 1997
  24. American Heart Association Missouri Affiliate Fellowship, 1997
  25. American Medical Association Education and Research Foundation, Florence A. Carter Fellowship Program in Leukemia Research, 1997
  26. National Research Service Award, NIH, 1997
  27. Children's Cancer Research Fund, 1997
  28. Minorities in Medical Oncology Award NIH, 1998
  29. Pediatric Scientist Development Training Program, 1999
  30. American Society for Hematology, Fellow Award, 2000
  31. American Heart Association Missouri Affiliate Fellowship, 2003
  32. Amgen Hematology and Oncology Fellowship Program, 2004
  33. American Cancer Society Institutional Research Grant, 2004
  34. Hope Street Kids Grant and Fellowship Awards, 2007
  35. ASCO Foundation Young Investigator’s Award (YIA), 2007
  36. Children's Discovery Institute; McDonnell Pediatric Cancer Center Fellowship, 2007
  37. St. Baldrick’s Post-Doctoral Fellowship for Childhood Cancer Research, 2008
  38. CTSA/ICTS-Washington University School of Medicine, 2008
  39. Pediatric Scientist Development Program (PSDP) Award, 2009-11
  40. St. Baldrick’s Post-Doctoral Fellowship for Childhood Cancer Research, 2009
 

Selected Publications by Current and Past Fellows

  1. Blunt AG, Lawshe A, Cunningham ML, et al: Overlapping expression and redundant activation of mesenchymal fibroblast growth factor (FGF) receptors by alternatively spliced FGF-8 ligands. Journal of Biological Chemistry 272:3733-8, 1997.
     
  2. Boudreaux JM, Towler DA: Synergistic induction of osteocalcin gene expression: identification of a bipartite element conferring fibroblast growth factor 2 and cyclic AMP responsiveness in the rat osteocalcin promoter. Journal of Biological Chemistry 271:7508-15, 1996.
     
  3. Brandt JM, Djouadi F, Kelly DP: Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. Journal of Biological Chemistry 273:23786-92, 1998.
     
  4. Crawford DF, Piwnica-Worms H: The G(2) DNA damage checkpoint delays expression of genes encoding mitotic regulators. Journal of Biological Chemistry 276:37166-37177, 2001.
     
  5. Dean J, Hayashi S, Albert C, King A, Karzon R and Hayashi R. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Ped Hem Onc, Feb 2008 30: 2.
     
  6. DeBaun MR, Glauser TA, Siegel M, et al: Noninvasive central nervous system imaging in sickle cell anemia. A preliminary study comparing transcranial Doppler with magnetic resonance angiography. Journal of Pediatric Hematology/Oncology 17:29-33, 1995. 
     
  7. DeBaun MR, Brown M, Kessler L: Screening for Wilms' tumor in children with high-risk congenital syndromes: considerations for an intervention trial. Medical & Pediatric Oncology 27:415-21, 1996.
     
  8. Djouadi F, Brandt JM, Weinheimer CJ, et al: The role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the control of cardiac lipid metabolism. Prostaglandins Leukotrienes amp; Essential Fatty Acids 60:339-43,1999.
     
  9. Druley TE, Vallania FML, Varley KE, Knowles OL, Bonds JA, Doniger SW, Wegner DJ, Hamvas A, Cole FS, Fay JC and Mitra RD. Accurate detection and quantification of rare allelic variants from the pooled genomic DNA of 1111 individuals. Nature Methods, advanced online publication, 01 March 2009 (doi:10.1038/nmeth.1307).
     
  10. Druley TE. Vallania FL. Wegner DJ. Varley KE. Knowles OL. Bonds JA. Robison SW. Doniger SW. Hamvas A Cole FS. Fay JC. Mitra RD. Quantification of rare allelic variants from pooled genomic DNA. Nature Methods. 6(4):263-5,2009.
     
  11. Druley TE. Hayashi R. Mansur DB. Zhang QJ. Barnes Y. Trinkaus K. Witty S. Thomas T. Klein EE. DiPersio JF. Adkins D. Shenoy S. Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBI. Bone Marrow Transplantation. 43(4):307-14, 2009 Feb.
     
  12. Frei-Jones MJ BA, Rogers ZR, Buchanan GR. Vaso-occlusive episodes in older children with sickle cell disease: emergency department management and pain assessment. J Peds 2007; Inpress.
     
  13. Frei-Jones MJ. Field JJ. DeBaun MR. Multi-modal intervention and prospective implementation of standardized sickle cell pain admission orders reduces 30-day readmission rate. Pediatric Blood
     
  14. Frei-Jones MJ. Field JJ. DeBaun MR. Risk factors for hospital readmission within 30 days: a new quality measure for children with sickle cell disease.[see comment]. Pediatric Blood & Cancer. 52(4):481-5, 2009 Apr.
     
  15. Gauvain KM, McKinstry RC, Mukherjee P, et al: Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging. AJR. American Journal of Roentgenology 177:449-54, 2001.
     
  16. Gomperts BN, Gong-Cooper X, Hackett BP: Foxj1 regulates basal body anchoring to the cytoskeleton of ciliated pulmonary epithelial cells. Journal of Cell Science 117:1329-37, 1329.
     
  17. Grossman WJ, Verbsky JW, Barchet W, et al: Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21:589-601, 2004.
     
  18. Grossman WJ, Verbsky JW, Tollefsen BL, et al: Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 104:2840-8, 2004.
     
  19. Hanson R.D., Hess JL, Yu BD, et al: Mammalian Trithorax and polycomb-group homologues are antagonistic regulators of homeotic development. Proceedings of the National Academy of Sciences of the United States of America 96:14372-7, 1999.
     
  20. Helmink BA. Bredemeyer AL. Lee BS. Huang CY. Sharma GG. Walker LM. Bednarski JJ. Lee WL. Pandita TK. Bassing CH. Sleckman BP. MRN complex function in the repair of chromosomal Rag-mediated DNA double-strand breaks. Journal of Experimental Medicine. 206(3):669-79, 2009 Mar16.
     
  21. Herron S, Bacak SJ, King A, et al: Inadequate recognition of education resources required for high-risk students with sickle cell disease. Archives of Pediatrics & Adolescent Medicine. 157:104, 2003.
     
  22. Hulbert ML. Scothorn DJ. Panepinto JA. Scott JP. Buchanan GR. Sarnaik S. Fallon R. Chu JY. Wang W. Casella JF. Resar L. Berman B. Adamkiewicz T. Hsu LL. Smith-Whitley K. Mahoney D. Woods G. Watanabe M. DeBaun MR. Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia Journal of Pediatrics. 149(5):710-2, 2006 Nov.
     
  23. Kanter J, Khan SY, Kelher M, Gore L, and Silliman CC. Oncogenic and angiogenic growth factors accumulate during routine storage of apheresis platelet concentrates. Clin Cancer Res. 15;14(12):3942-7, 2008 Jun.
     
  24. Kelly ME, Chan AC: Regulation of B cell function by linker proteins. Current Opinion in Immunology 12:267-75, 2000.
     
  25. King AA, Tang S, Ferguson KL, et al: An education program to increase teacher knowledge about sickle cell disease. Journal of School Health 75:11-4, 2005. 
     
  26. Link DC, Kunter G, Kasai Y, Zhao Y, Miner T, McLellan MD, Ries RE, Kapur D, Nagarajan R, Dale DC, Bolyard AA, Boxer LA, Welte K, Zeidler C, Donadieu J, Bellanné-Chantelot C, Vardiman JW, Caligiuri MA, Bloomfield CA, DiPersio JF, Tomasson MH, Graubert TA, Westervelt P, Watson M, Shannon W, Baty J, Mardis ER, Wilson RK, and Ley TJ. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood, Sep 2007; 110: 1648 - 1655.
     
  27. Liu F*, Kunter G*, Krem M*, Eades W, Cain J, Tomasson M, Henninghausen L, and Link DC. G-CSF receptor mutations found in patients with severe congenital neutropenia induce hematopoietic stem self-renewal that is mediated by STAT5. JCI, 118:946-55, 2008. *These authors contributed equally to this study.
     
  28. Luchtman-Jones L, Broze GJ: The current status of coagulation. Annals of Medicine 27:47-52, 1995.
     
  29. Mascotti DP, Rup D, Thach RE: Regulation of iron metabolism: translational effects mediated by iron, heme, and cytokines. Annual Review of Nutrition 15:239-61, 1995.
     
  30. Mascotti DP, Goessling LS, Rup D, et al: Effects of the ferritin open reading frame on translational induction by iron. Progress in Nucleic Acid Research & Molecular Biology 55:121-34,1996.
     
  31. McDonald S. Wilson DB. Pumbo E. Kulkarni S. Mason PJ. Else T. Bessler M. Ferkol T. Shenoy S. Acquired monosomy 7 myelodysplastic syndrome in a child with clinical features suggestive of dyskeratosis congenita and IMAGe association. Pediatr Blood Cancer. In press.
     
  32. McLemore ML, Grewal S, Liu F, et al: STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. Immunity 14:193-204, 2001.
     
  33. Newberry EP, Boudreaux JM, Towler DA: The rat osteocalcin fibroblast growth factor (FGF)-responsive element: an okadaic acid-sensitive, FGF-selective transcriptional response motif. Molecular Endocrinology 10:1029-40, 1996.
     
  34. RaoA. HulbertM. Wilson DB. Severe hypertriglyceridemia in an infant with red cell pyruvate kinase deficiency. Indian Pediatrics. 44(4):303-5, 2007 Apr.
     
  35. Rao A. Kamani N. Filipovich A. Lee SM. Davies SM. Dalal J. Shenoy S. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood. 109(1):383-5, 2007 Jan 1.
     
  36. RaoA, Kelly M, Musselman M, Ramadas J, Grossman W and Shenoy S. Safety, efficacy and immune reconstitution after anti-CD20 monoclonal antibody for pediatric autoimmune cytopenias. Pediatric Blood and Cancer, 2007. In press.
     
  37. Richards MK, Liu F, Iwasaki H, et al: Pivotal role of granulocyte colony-stimulating factor in the development of progenitors in the common myeloid pathway.Blood 102:3562-8, 2003.
     
  38. Saylors RL, 3rd, Sidransky D, Friedman HS, et al: Infrequent p53 gene mutations in medulloblastomas. Cancer Research 51:4721-3, 1991.
     
  39. Schaefer A, Jasinski M, Bessler M: High-dose cyclophosphamide does not eradicate paroxysmal nocturnal haemoglobinuria haematopoiesis in mice carrying a Piga gene mutation. British Journal of Haematology. 120:903-6,2003.
     
  40. Schuettpelz LG. McDonald S. Whitesell K. Desruisseau DM. Grange DK. Gurnett CA. Wilson DB. Pilocytic astrocytoma in a child with Noonan syndrome. Pediatr Blood Cancer; 2009 Jul 20 [Epub ahead of print]
     
  41. Wasson JC, Saylors RL, 3rd, Zeltzer P, et al: Oncogene amplification in pediatric brain tumors. Cancer Research 50:2987-90, 1990.
     
  42. Yamaguchi Y, Heiny ME, Shimizu N, et al: Expression of the Wilson disease gene is deficient in the Long-Evans Cinnamon rat. Biochemical Journal 301:1-4, 1994.
     
  43. Yamaguchi Y, Heiny ME, Suzuki M, et al: Biochemical characterization and intracellular localization of the Menkes disease protein. Proceedings of the National Academy of Sciences of the United States of America 93:14030-5, 1996.
     
  44. Yang E, Zha J, Jockel J, et al: Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80:285-91, 1995.
     
  45. Yu BD, Hanson R.D., Hess JL, et al: MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. Proceedings of the National Academy of Sciences of the United States of America 95:10632-6, 1998.
     
  46. Zha J, Harada H, Yang E, et al: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87:619-28, 1996.

The Application Process

The Washington University School of Medicine Hematology/Oncology Fellowship Program participates in the Electronic Residency Application Service (ERAS).  An application and directions may be found at http://www.aamc.org/students/eras/start.htm.

Fellowship applicants may begin applying to our fellowship program November 15.  We will consider applications submitted by our March 1, 2009 deadline.

A complete application consists of the following: Dean's letter, transcript of grades, USMLE scores, personal statement, and three letters of recommendation written by physicians with whom you have worked during medical training.  Preferably, one letter will be written by the chairman of your Department of Pediatrics or your pediatric residency program director.  Foreign medical graduates will also need a valid ECFMG certificate.

For more information, please contact:
Peg Greco Schneider, Education Coordinator
(314) 454-4327
schneider_p@kids.wustl.edu
 

Contact

Robert J. Hayashi, M.D.
C/O Peg Greco Schneider, Fellowship Administrator
Division of Hematology/Oncology
Department of Pediatrics
Washington University School of Medicine
660 S. Euclid Ave., Campus Box 8116
St. Louis, MO 63110
(314) 454-4327 (Voice)
(314) 454-4283 (Fax)

 


 

 


 

 

Introduction

The division has a nationally recognized fellowship program designed to train specialist pediatricians seeking a career in academic pediatric hematology/oncology.  Since our faculty has considerable strength in clinical and basic investigation, the program is well suited to candidates interested in both tracks.  The program strives to not only make the trainee highly skilled in clinical care, but also capable of designing and performing sophisticated biomedical investigation that focuses on understanding and treating the childhood diseases as broadly defined by our specialty.
 
In order to train physicians appropriately for careers in this field, the fellowship lasts "three-plus" years.  The first-year fellow has strictly clinical responsibilities with every third week on call from home.  In addition to six months as supervisor of the in-house clinical service, the fellow rotates on electives in laboratories such as coagulation/blood bank, HLA lab, cyogenetics, molecular diagnostics and clinical services including radiation therapy, pathology, pheresis, adult hematology and bone marrow transplant.  This broad curriculum provides a strong foundation for the fellow ensuring that he or she is well equipped with an extensive and sophisticated fund of knowledge.
 
After the first year, the fellow begins an individualized program of clinical or basic science investigation mentored by a faculty investigator at the School of Medicine.  During this period, the trainee is expected to develop the knowledge, thought processes and laboratory skills necessary to develop into an independent, competitive investigator in today's scientific community.  In order to focus on his or her investigation, the fellow's clinical responsibilities are limited to attending one clinic day each week and two clinical conferences.
The program has a long history of developing successful physician investigators.  Our fellows have published numerous articles in highly competitive areas of biomedical research, and they continue to maintain a history of success in acquiring extramural funding support.  Thus, fellows who graduate from our program can be confident that they will meet the challenges they will face as they advance through their academic careers.

 

Current Fellows

Samuel Anim, M.D. 

  • M.D. – University of Science and Technology Medical School, Ghana, 2001
  • Residency – Michigan State University/The Children's Hospotal at Bronson, Kalamazoo, MI, 2006-2009
  • Currently proceeding through the clinical first year rotations
Sharon McDonald, M.D. 
  • M.D. – University of Mississippi, 2004
  • Residency – University of Arkansas/Little Rock Children's Hospital, 2004-2007
  • Research: Characterization of the role of dyskerin, the known defective protein in dyskeratosis congenita, in the repair of damaged DNA
Laura Schuettpelz, M.D., Ph.D.
  • M.D. – Northwestern University School of Medicine, 2005
  • Residency – Washington University School of Medicine, 2005-2008
  • Research: Elucidating the role of G-CSF on hematopoietic stem cells
Edward Ziga, M.D.
  • M.D. – University of Science and Technology Medical School, Ghana, 1990
  • Residency – St. Joseph's Children's Hospital, New Jersey, 2004 - 2007
  • Currently proceeding through the clinical first year rotations

 

Awards and Grants Received by Current and Past Fellows

  1. National Research Service Award, NCI, 1991
  2. Functional Domains of NGF-IA, National Research Service Award, NIH, 1991
  3. Regulation of Lens Gap Junctions, National Research Service Award, NIH, 1991
  4. National Research Service Award, NIH, 1992
  5. Howard Hughes Medical Institute, Postdoctoral Fellowship, 1993
  6. American Cancer Society Post Doctoral Fellowship, 1993
  7. Pfizer Inc. Postdoctoral Fellowship, 1993
  8. American Association for Cancer Research, 1992
  9. American Heart Association Missouri Affiliate Fellowship, 1994
  10. Pediatric Medical Oncology Physician Scientist Award NIH, 1992
  11. Leukemia Society Fellowship Award, 1993
  12. Clinical Investigator Development Award NIH, 1994
  13. American Cancer Society Clinical Oncology Fellowship, 1994
  14. Pediatric Oncology Physician Scientist Award, 1994
  15. Robert Steel Foundation Research Fellowship, 1994
  16. Howard Hughes Medical Institute, Postdoctoral Research Fellowship for Physicians, 1995
  17. Clinical Investigator Development Award NIH, 1995
  18. Pediatric Medical Oncology Physician scientist Award, NIH, 1995
  19. American Cancer Society Clinical Oncology Fellowship, 1995
  20. Children's Brittle Bone foundation Fellowship, 1996
  21. American Heart Association Missouri Affiliate Fellowship, 1996
  22. Cure Foundation Fellowship, 1996
  23. American Society for Hematology, Fellow Award, 1997
  24. American Heart Association Missouri Affiliate Fellowship, 1997
  25. American Medical Association Education and Research Foundation, Florence A. Carter Fellowship Program in Leukemia Research, 1997
  26. National Research Service Award, NIH, 1997
  27. Children's Cancer Research Fund, 1997
  28. Minorities in Medical Oncology Award NIH, 1998
  29. Pediatric Scientist Development Training Program, 1999
  30. American Society for Hematology, Fellow Award, 2000
  31. American Heart Association Missouri Affiliate Fellowship, 2003
  32. Amgen Hematology and Oncology Fellowship Program, 2004
  33. American Cancer Society Institutional Research Grant, 2004
  34. Hope Street Kids Grant and Fellowship Awards, 2007
  35. ASCO Foundation Young Investigator’s Award (YIA), 2007
  36. Children's Discovery Institute; McDonnell Pediatric Cancer Center Fellowship, 2007
  37. St. Baldrick’s Post-Doctoral Fellowship for Childhood Cancer Research, 2008
  38. CTSA/ICTS-Washington University School of Medicine, 2008
  39. Pediatric Scientist Development Program (PSDP) Award, 2009-11
  40. St. Baldrick’s Post-Doctoral Fellowship for Childhood Cancer Research, 2009
 

Selected Publications by Current and Past Fellows

  1. Blunt AG, Lawshe A, Cunningham ML, et al: Overlapping expression and redundant activation of mesenchymal fibroblast growth factor (FGF) receptors by alternatively spliced FGF-8 ligands. Journal of Biological Chemistry 272:3733-8, 1997.
     
  2. Boudreaux JM, Towler DA: Synergistic induction of osteocalcin gene expression: identification of a bipartite element conferring fibroblast growth factor 2 and cyclic AMP responsiveness in the rat osteocalcin promoter. Journal of Biological Chemistry 271:7508-15, 1996.
     
  3. Brandt JM, Djouadi F, Kelly DP: Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. Journal of Biological Chemistry 273:23786-92, 1998.
     
  4. Crawford DF, Piwnica-Worms H: The G(2) DNA damage checkpoint delays expression of genes encoding mitotic regulators. Journal of Biological Chemistry 276:37166-37177, 2001.
     
  5. Dean J, Hayashi S, Albert C, King A, Karzon R and Hayashi R. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Ped Hem Onc, Feb 2008 30: 2.
     
  6. DeBaun MR, Glauser TA, Siegel M, et al: Noninvasive central nervous system imaging in sickle cell anemia. A preliminary study comparing transcranial Doppler with magnetic resonance angiography. Journal of Pediatric Hematology/Oncology 17:29-33, 1995. 
     
  7. DeBaun MR, Brown M, Kessler L: Screening for Wilms' tumor in children with high-risk congenital syndromes: considerations for an intervention trial. Medical & Pediatric Oncology 27:415-21, 1996.
     
  8. Djouadi F, Brandt JM, Weinheimer CJ, et al: The role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the control of cardiac lipid metabolism. Prostaglandins Leukotrienes amp; Essential Fatty Acids 60:339-43,1999.
     
  9. Druley TE, Vallania FML, Varley KE, Knowles OL, Bonds JA, Doniger SW, Wegner DJ, Hamvas A, Cole FS, Fay JC and Mitra RD. Accurate detection and quantification of rare allelic variants from the pooled genomic DNA of 1111 individuals. Nature Methods, advanced online publication, 01 March 2009 (doi:10.1038/nmeth.1307).
     
  10. Druley TE. Vallania FL. Wegner DJ. Varley KE. Knowles OL. Bonds JA. Robison SW. Doniger SW. Hamvas A Cole FS. Fay JC. Mitra RD. Quantification of rare allelic variants from pooled genomic DNA. Nature Methods. 6(4):263-5,2009.
     
  11. Druley TE. Hayashi R. Mansur DB. Zhang QJ. Barnes Y. Trinkaus K. Witty S. Thomas T. Klein EE. DiPersio JF. Adkins D. Shenoy S. Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBI. Bone Marrow Transplantation. 43(4):307-14, 2009 Feb.
     
  12. Frei-Jones MJ BA, Rogers ZR, Buchanan GR. Vaso-occlusive episodes in older children with sickle cell disease: emergency department management and pain assessment. J Peds 2007; Inpress.
     
  13. Frei-Jones MJ. Field JJ. DeBaun MR. Multi-modal intervention and prospective implementation of standardized sickle cell pain admission orders reduces 30-day readmission rate. Pediatric Blood
     
  14. Frei-Jones MJ. Field JJ. DeBaun MR. Risk factors for hospital readmission within 30 days: a new quality measure for children with sickle cell disease.[see comment]. Pediatric Blood & Cancer. 52(4):481-5, 2009 Apr.
     
  15. Gauvain KM, McKinstry RC, Mukherjee P, et al: Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging. AJR. American Journal of Roentgenology 177:449-54, 2001.
     
  16. Gomperts BN, Gong-Cooper X, Hackett BP: Foxj1 regulates basal body anchoring to the cytoskeleton of ciliated pulmonary epithelial cells. Journal of Cell Science 117:1329-37, 1329.
     
  17. Grossman WJ, Verbsky JW, Barchet W, et al: Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21:589-601, 2004.
     
  18. Grossman WJ, Verbsky JW, Tollefsen BL, et al: Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 104:2840-8, 2004.
     
  19. Hanson R.D., Hess JL, Yu BD, et al: Mammalian Trithorax and polycomb-group homologues are antagonistic regulators of homeotic development. Proceedings of the National Academy of Sciences of the United States of America 96:14372-7, 1999.
     
  20. Helmink BA. Bredemeyer AL. Lee BS. Huang CY. Sharma GG. Walker LM. Bednarski JJ. Lee WL. Pandita TK. Bassing CH. Sleckman BP. MRN complex function in the repair of chromosomal Rag-mediated DNA double-strand breaks. Journal of Experimental Medicine. 206(3):669-79, 2009 Mar16.
     
  21. Herron S, Bacak SJ, King A, et al: Inadequate recognition of education resources required for high-risk students with sickle cell disease. Archives of Pediatrics & Adolescent Medicine. 157:104, 2003.
     
  22. Hulbert ML. Scothorn DJ. Panepinto JA. Scott JP. Buchanan GR. Sarnaik S. Fallon R. Chu JY. Wang W. Casella JF. Resar L. Berman B. Adamkiewicz T. Hsu LL. Smith-Whitley K. Mahoney D. Woods G. Watanabe M. DeBaun MR. Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia Journal of Pediatrics. 149(5):710-2, 2006 Nov.
     
  23. Kanter J, Khan SY, Kelher M, Gore L, and Silliman CC. Oncogenic and angiogenic growth factors accumulate during routine storage of apheresis platelet concentrates. Clin Cancer Res. 15;14(12):3942-7, 2008 Jun.
     
  24. Kelly ME, Chan AC: Regulation of B cell function by linker proteins. Current Opinion in Immunology 12:267-75, 2000.
     
  25. King AA, Tang S, Ferguson KL, et al: An education program to increase teacher knowledge about sickle cell disease. Journal of School Health 75:11-4, 2005. 
     
  26. Link DC, Kunter G, Kasai Y, Zhao Y, Miner T, McLellan MD, Ries RE, Kapur D, Nagarajan R, Dale DC, Bolyard AA, Boxer LA, Welte K, Zeidler C, Donadieu J, Bellanné-Chantelot C, Vardiman JW, Caligiuri MA, Bloomfield CA, DiPersio JF, Tomasson MH, Graubert TA, Westervelt P, Watson M, Shannon W, Baty J, Mardis ER, Wilson RK, and Ley TJ. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood, Sep 2007; 110: 1648 - 1655.
     
  27. Liu F*, Kunter G*, Krem M*, Eades W, Cain J, Tomasson M, Henninghausen L, and Link DC. G-CSF receptor mutations found in patients with severe congenital neutropenia induce hematopoietic stem self-renewal that is mediated by STAT5. JCI, 118:946-55, 2008. *These authors contributed equally to this study.
     
  28. Luchtman-Jones L, Broze GJ: The current status of coagulation. Annals of Medicine 27:47-52, 1995.
     
  29. Mascotti DP, Rup D, Thach RE: Regulation of iron metabolism: translational effects mediated by iron, heme, and cytokines. Annual Review of Nutrition 15:239-61, 1995.
     
  30. Mascotti DP, Goessling LS, Rup D, et al: Effects of the ferritin open reading frame on translational induction by iron. Progress in Nucleic Acid Research & Molecular Biology 55:121-34,1996.
     
  31. McDonald S. Wilson DB. Pumbo E. Kulkarni S. Mason PJ. Else T. Bessler M. Ferkol T. Shenoy S. Acquired monosomy 7 myelodysplastic syndrome in a child with clinical features suggestive of dyskeratosis congenita and IMAGe association. Pediatr Blood Cancer. In press.
     
  32. McLemore ML, Grewal S, Liu F, et al: STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. Immunity 14:193-204, 2001.
     
  33. Newberry EP, Boudreaux JM, Towler DA: The rat osteocalcin fibroblast growth factor (FGF)-responsive element: an okadaic acid-sensitive, FGF-selective transcriptional response motif. Molecular Endocrinology 10:1029-40, 1996.
     
  34. RaoA. HulbertM. Wilson DB. Severe hypertriglyceridemia in an infant with red cell pyruvate kinase deficiency. Indian Pediatrics. 44(4):303-5, 2007 Apr.
     
  35. Rao A. Kamani N. Filipovich A. Lee SM. Davies SM. Dalal J. Shenoy S. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood. 109(1):383-5, 2007 Jan 1.
     
  36. RaoA, Kelly M, Musselman M, Ramadas J, Grossman W and Shenoy S. Safety, efficacy and immune reconstitution after anti-CD20 monoclonal antibody for pediatric autoimmune cytopenias. Pediatric Blood and Cancer, 2007. In press.
     
  37. Richards MK, Liu F, Iwasaki H, et al: Pivotal role of granulocyte colony-stimulating factor in the development of progenitors in the common myeloid pathway.Blood 102:3562-8, 2003.
     
  38. Saylors RL, 3rd, Sidransky D, Friedman HS, et al: Infrequent p53 gene mutations in medulloblastomas. Cancer Research 51:4721-3, 1991.
     
  39. Schaefer A, Jasinski M, Bessler M: High-dose cyclophosphamide does not eradicate paroxysmal nocturnal haemoglobinuria haematopoiesis in mice carrying a Piga gene mutation. British Journal of Haematology. 120:903-6,2003.
     
  40. Schuettpelz LG. McDonald S. Whitesell K. Desruisseau DM. Grange DK. Gurnett CA. Wilson DB. Pilocytic astrocytoma in a child with Noonan syndrome. Pediatr Blood Cancer; 2009 Jul 20 [Epub ahead of print]
     
  41. Wasson JC, Saylors RL, 3rd, Zeltzer P, et al: Oncogene amplification in pediatric brain tumors. Cancer Research 50:2987-90, 1990.
     
  42. Yamaguchi Y, Heiny ME, Shimizu N, et al: Expression of the Wilson disease gene is deficient in the Long-Evans Cinnamon rat. Biochemical Journal 301:1-4, 1994.
     
  43. Yamaguchi Y, Heiny ME, Suzuki M, et al: Biochemical characterization and intracellular localization of the Menkes disease protein. Proceedings of the National Academy of Sciences of the United States of America 93:14030-5, 1996.
     
  44. Yang E, Zha J, Jockel J, et al: Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80:285-91, 1995.
     
  45. Yu BD, Hanson R.D., Hess JL, et al: MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. Proceedings of the National Academy of Sciences of the United States of America 95:10632-6, 1998.
     
  46. Zha J, Harada H, Yang E, et al: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87:619-28, 1996.

The Application Process

The Washington University School of Medicine Hematology/Oncology Fellowship Program participates in the Electronic Residency Application Service (ERAS).  An application and directions may be found at http://www.aamc.org/students/eras/start.htm.

Fellowship applicants may begin applying to our fellowship program November 15.  We will consider applications submitted by our March 1, 2009 deadline.

A complete application consists of the following: Dean's letter, transcript of grades, USMLE scores, personal statement, and three letters of recommendation written by physicians with whom you have worked during medical training.  Preferably, one letter will be written by the chairman of your Department of Pediatrics or your pediatric residency program director.  Foreign medical graduates will also need a valid ECFMG certificate.

For more information, please contact:
Peg Greco Schneider, Education Coordinator
(314) 454-4327
schneider_p@kids.wustl.edu
 

Contact

Robert J. Hayashi, M.D.
C/O Peg Greco Schneider, Fellowship Administrator
Division of Hematology/Oncology
Department of Pediatrics
Washington University School of Medicine
660 S. Euclid Ave., Campus Box 8116
St. Louis, MO 63110
(314) 454-4327 (Voice)
(314) 454-4283 (Fax)

 
 
dna
 
| Terms Of Use | Privacy Statement | Copyright 2009 by Washington University in St. Louis, School of Medicine | |